BRIEF-Neurosense Secures Key FDA Meeting To Advance Its Phase 3 ALS Trial And NDA Submission

Reuters10-28

Oct 28 (Reuters) - Neurosense Therapeutics Ltd :

* NEUROSENSE SECURES KEY FDA MEETING TO ADVANCE ITS PHASE 3 ALS TRIAL AND NDA SUBMISSION

* NEUROSENSE THERAPEUTICS: FDA TYPE C MEETING SCHEDULED FOR NOV 6 FOR PHASE 3 ALS TRIAL

* NEUROSENSE: IN CANADA, PLANS TO SUBMIT DOSSIER IN Q2 2025, WITH REGULATORY DECISION ON COMMERCIALIZATION EXPECTED BY Q1 2026

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2478010006?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-28 20:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478010006","market":"us","top_or_hot":-1,"title":"BRIEF-Neurosense Secures Key FDA Meeting To Advance Its Phase 3 ALS Trial And NDA Submission","media":"Reuters","content":"<html><body><p>Oct 28 (Reuters) - <a href=\"https://laohu8.com/S/NRSN\">Neurosense Therapeutics Ltd</a>   :</p><p>   * NEUROSENSE SECURES KEY FDA MEETING TO ADVANCE ITS PHASE 3 ALS TRIAL AND NDA SUBMISSION</p><p>   * NEUROSENSE THERAPEUTICS: FDA TYPE C MEETING SCHEDULED FOR NOV 6 FOR PHASE 3 ALS TRIAL</p><p>   * NEUROSENSE: IN CANADA, PLANS TO SUBMIT DOSSIER IN Q2 2025, WITH REGULATORY DECISION ON COMMERCIALIZATION EXPECTED BY Q1 2026</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Neurosense Secures Key FDA Meeting To Advance Its Phase 3 ALS Trial And NDA Submission</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Neurosense Secures Key FDA Meeting To Advance Its Phase 3 ALS Trial And NDA Submission\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-28 20:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oct 28 (Reuters) - Neurosense Therapeutics Ltd   :   * NEUROSENSE SECURES KEY FDA MEETING TO ADVANCE ITS PHASE 3 ALS TRIAL AND NDA SUBMISSION   * NEUROSENSE THERAPEUTICS: FDA TYPE C MEETING SCHEDULED ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2478010006","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478010006","pubTimestamp":1730119994,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 28  - Neurosense Therapeutics Ltd   :   * NEUROSENSE SECURES KEY FDA MEETING TO ADVANCE ITS PHASE 3 ALS TRIAL AND NDA SUBMISSION   * NEUROSENSE THERAPEUTICS: FDA TYPE C MEETING SCHEDULED FOR NOV 6 FOR PHASE 3 ALS TRIAL   * NEUROSENSE: IN CANADA, PLANS TO SUBMIT DOSSIER IN Q2 2025, WITH REGULATORY DECISION ON COMMERCIALIZATION EXPECTED BY Q1 2026Source text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NRSN":"Neurosense Therapeutics Ltd"},"translate_title":"简介-Neurosense获得FDA重要会议以推进其3期ALS试验和NDA提交","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRSN":0.9},"content_text":"Oct 28 (Reuters) - Neurosense Therapeutics Ltd   :   * NEUROSENSE SECURES KEY FDA MEETING TO ADVANCE ITS PHASE 3 ALS TRIAL AND NDA SUBMISSION   * NEUROSENSE THERAPEUTICS: FDA TYPE C MEETING SCHEDULED FOR NOV 6 FOR PHASE 3 ALS TRIAL   * NEUROSENSE: IN CANADA, PLANS TO SUBMIT DOSSIER IN Q2 2025, WITH REGULATORY DECISION ON COMMERCIALIZATION EXPECTED BY Q1 2026Source text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2478010006"}